What is the clinical evidence from this study?

Study design: Other. Population: Left ventricular hypertrophy and hypertension (n=30). Intervention: Naringenin vs. L-NAME + saline. Primary outcome: Left ventricular hypertrophy (interventricular septal thickness, left ventricular posterior wall thickness, cardiomyocyte cross-sectional area) (p=<0.05).

June 7, 2018Experimental and Therapeutic MedicineOpen Access

Naringenin inhibits NG‑nitro‑L‑arginine methyl ester‑induced hypertensive left ventricular hypertrophy by decreasing angiotensin‑converting enzyme 1 expression

Q: What are the key findings of this study?

Naringenin significantly attenuated left ventricular hypertrophy and decreased angiotensin II and ACE1 protein levels in myocardial tissues in rats with L-NAME-induced hypertension.

Q: What does this research mean for the field?

Naringenin significantly attenuates left ventricular hypertrophy and decreases angiotensin II and ACE1 protein levels in myocardial tissues in rats with L-NAME-induced hypertension, without significantly affecting blood pressure. Novelty: ClaimNovelty.INCREMENTAL. Consensus alignment: ConsensusAlignment.NEUTRAL.

View Full Paper

Ask AI

Bookmark

Key result

Naringenin significantly attenuated left ventricular hypertrophy and decreased angiotensin II and ACE1 protein levels in myocardial tissues in rats with L-NAME-induced hypertension.

Why the study?

Does naringenin prevent left ventricular hypertrophy in a rat model of L-NAME-induced hypertension?

Population

30 male Sprague-Dawley rats (160-180 g) divided into three groups (n=10 per group).

Comparison

Naringenin 100 mg/kg/day administered by gavage… vs L-NAME + saline, and a control group receiving…

Design

Preclinical

Follow-up

56 days

Authors

YGYanxiang GaoGuangzhou University of Chinese Medicine ZWZhizhi WangInstitute on Governance YZYayun ZhangWenzhou Medical University

Discussion

Member takes

Implication

Naringenin effects on LVH should not change practice; hypothesis-generating for ACE1/Ang II modulation in hypertensive remodeling models.

Structured PICO

Does naringenin prevent left ventricular hypertrophy in a rat model of L-NAME-induced hypertension?

Population

30 male Sprague-Dawley rats with L-NAME-induced hypertension treated and followed for 8 weeks.

Intervention

Naringenin (NGN) 100 mg/kg/day administered by gavage daily for 56 days, in addition to L-NAME 50 mg/kg/day.

Comparator

L-NAME (50 mg/kg/day) + saline, and a control group receiving saline + saline.

Outcome

Left ventricular hypertrophy assessed by echocardiography (IVSth, LVPWth) and histology, and expression of Ang II and ACE1 at 56 days.surrogate

Main Result

p-value: p=<0.05

Naringenin attenuates pressure overload-induced left ventricular hypertrophy in rats by downregulating ACE1 and Ang II expression in cardiac tissue.

Limitations

Animal model, which may not fully translate to human pathology
Naringenin did not significantly lower the elevation of systolic blood pressure induced by L-NAME
The study only evaluated the early compensatory phase of hypertensive heart damage

Cite This Study

Gao et al. (2018) studied Left ventricular hypertrophy and hypertension (n=30). Naringenin vs. L-NAME + saline was evaluated on Left ventricular hypertrophy (interventricular septal thickness, left ventricular posterior wall thickness, cardiomyocyte cross-sectional area) (p=<0.05). Naringenin significantly attenuated left ventricular hypertrophy and decreased angiotensin II and ACE1 protein levels in myocardial tissues in rats with L-NAME-induced hypertension.

synapsesocial.com/papers/6a242fffb7e293e61ca666aa https://doi.org/10.3892/etm.2018.6258

View Full Paper

Ask AI

Bookmark

Naringenin inhibits NG‑nitro‑L‑arginine methyl ester‑induced hypertensive left ventricular hypertrophy by decreasing angiotensin‑converting enzyme 1 expression

Discussion

Member takes

Implication

Structured PICO

Main Result

Limitations

Cite This Study

Naringenin inhibits NG‑nitro‑L‑arginine methyl ester‑induced hypertensive left ventricular hypertrophy by decreasing angiotensin‑converting enzyme 1 expression

Discussion

Member takes

Implication

Structured PICO

Main Result

Limitations

Cite This Study

Also Consider

Also Consider